Identification of Evolutionary Trade-Offs Associated with High-Level Colistin Resistance in Acinetobacter baumannii
Kusumita AcharyaiD, Upasana Bhattacharya, Shatarupa Biswas, Nilanjan Pradhan, Sunandini Bhattacharya, Mallika Ghosh, Arijit BhattacharyaiD
Abstract
ABSTRACTColistin (COL) belongs to the polymyxin group of drugs which possesses a positive charge and interacts with lipopolysaccharide (LPS) of Gram-negative bacterial outer membrane. Additionally, it can penetrate the cell membrane and disrupt the integrity of the phospholipid leading to cell death. Resistance against COL has been reported in Acinetobacter baumannii, a bacteria in the ESKAPE group of priority pathogens of the World Health Organization. Multiple and pan-drug-resistant strains of A. baumannii are rising in many medical facilities and they are becoming resistant to last-resort antibiotics including colistin. Though plasmid-encoded acquisition of mcr-1 has been associated with clinical resistance, drug efflux, complete loss of LPS by inactivation of the biosynthetic pathway (lpxACD), and modifications of target LPS by-products of chromosomal pmrCAB genes has been ascribed with resistance evolution against COL. To further delve into the evolutionary dynamics of COL-resistance here we report experimental evolution of extreme COL-resistance by adaptive evolution of the reference strain A. baumannii ATCC19606. Phenotypic characterization has been performed for the evolved strains, which demonstrated hyperbiofilm phenotype and striking decrease in fitness. A comprehensive antibiotic susceptibility profiling has been performed on the evolved strains. Whole genome sequencing of the resistant strains led to the identification of mutations prospectively associated with COL resistance. Phenotypic characterization of three COL-resistant clinical isolates of A. baumannii revealed similarity with experimentally evolved resistant mutants at least in one of the isolates.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 1.67
- Field percentile
- top 16%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Resistance, heteroresistance and fitness costs drive colistin treatment failure during Acinetobacter baumannii murine pneumonia
Juan Hernandez-Bird, Bixi He, … Ralph R. Isberg·Proceedings of the National Academy of SciencesPeer-reviewed·Dec 29, 2025
- Paucity of adaptive selection in PmrAB two-component system may resist emergence of colistin resistance in Acinetobacter baumannii
S. Pagal, R. Saranathan, … K. Prashanth·bioRxiv·Sep 15, 2019
- Adaptation of Acinetobacter baumannii to colistin exposure: Laboratory mimicking of a clinical case
E. Oralkan, S. Keske, … F. Can·bioRxiv·Dec 19, 2018
- A Clinically Silent Resistance Phenotype That Promotes Acinetobacter baumannii Survival During Colistin Therapy
Muneer Oladipupo Yaqub, Namrata Bonde, … Nicholas Allen Dillon·bioRxiv·Jan 21, 2026
- Colistin resistance in Acinetobacter baumannii is driven by multiple genomic traits: Evaluating the role of ISAba1-driven eptA overexpression among Indian isolates
S. Vijayakumar, J. J. Jacob, … B. Veeraraghavan·bioRxiv·Jan 7, 2021
- Colistin heteroresistance and the involvement of the PmrAB regulatory system in Acinetobacter baumannii
Y. Charretier, S. M. Diene, … J. Schrenzel·bioRxiv·Apr 25, 2018